AB
ABT
ABBOTT LABORATORIES
$91.25
+0.83%
$157.6B
No data for this timeframe.
Vol
Market Cap$157.6B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (71%)
Inst. Holders10 funds
Inst. Value$37.2B
Inst. Activity2 buys / 1 sells
Insider Activity2B / 6S
Insider Net $$642.5K
Reddit Sentiment71° Bullish
SEC Reports11
Congressional8 trades
Recent Activity
Jul 15, 2026
earnings_calendar
ABT Q2 2026 Earnings Before Market Open — 2026-07-15
EPS est: $1.39 | Rev est: $12.1B
Jun 8, 2026
Event
United States v. James Abbott
Court ruling from Court of Appeals for the D.C. Circuit. Docket: 25-5352
May 31, 2026
SEC
5 firms acted on ABT: Freedom Broker, Benchmark, Jefferies, Oppenheimer, Piper Sandler
ANALYST-UPGRADE — Impact 4/10
May 28, 2026
SEC
The Ninth Circuit affirmed the district court's dismissal of a pro se plaintiff's employment claims against Abbott Labor
COURT-RULING — Impact 1/10
May 27, 2026
Congress
Josh Gottheimer sell
$1,001 - $15,000 — House
May 1, 2026
SEC
Freedom Broker upgrades ABT to Buy — PT $120 (+32% upside) on cluster action
ANALYST-UPGRADE — Impact 4/10
Apr 28, 2026
Insider
Moreland Mary K sold 5,314 shares
EXECUTIVE VICE PRESIDENT @ $94.41 ($501.7K)
Apr 27, 2026
Insider
STARKS DANIEL J bought 10,000 shares
Director @ $92.65 ($926.5K)
Price Targets
$117.29
+28.5% upside
Strong Buy
Current $91.25
Low $92.00
Median $115.00
High $135.00
24 analysts
$92.00
$135.00
Analyst Ratings
10Strong Buy
14Buy
10Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Apr 17, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.28 | $1.26 — $1.29 | 1% YoY | 22 |
| Next Q | $1.42 | $1.40 — $1.45 | 9% YoY | 22 |
| Current FY | $5.48 | $5.40 — $5.71 | 6% YoY | 24 |
| Next FY | $6.06 | $5.95 — $6.20 | 11% YoY | 24 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $22.0B | — |
| MORGAN STANLEY | $4.6B | — |
| NORGES BANK | $2.9B | NEW |
| BANK OF AMERICA CORP | $2.5B | — |
| WELLS FARGO & COMPANY/MN | $2.1B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 28, 2026 | Moreland Mary | I | $501.7K |
| Apr 27, 2026 | STARKS DANIEL | BUY | $926.5K |
| Apr 24, 2026 | Ahuja Nita | A | $0.00 |
| Apr 24, 2026 | Babineaux-Fontenot Claire | A | $0.00 |
| Apr 24, 2026 | Blount Sally | A | $0.00 |
Reddit Sentiment
71°▼
Bullish
Bearish
Neutral
Bullish
Congressional Trades
6 members: 3 buys, 4 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Josh Gottheimer | D | SELL | $1,001 - $15,000 |
| Laura Friedman | D | EXCHANGE | $1,001 - $15,000 |
| Rich McCormick | R | BUY | $1,001 - $15,000 |
10 institutional holders with $37.2B total value (296,752,791 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, NORGES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 175,556,716 | $22.0B | 59.2% | — |
| 2 | MORGAN STANLEY | 36,727,533 | $4.6B | 12.4% | — |
| 3 | NORGES BANK | 23,456,714 | $2.9B | 7.9% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 19,830,623 | $2.5B | 6.7% | — |
| 5 | WELLS FARGO & COMPANY/MN | 16,543,457 | $2.1B | 5.6% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 13,189,528 | $1.7B | 4.4% | NEW |
| 7 | FMR LLC | 9,627,363 | $1.2B | 3.2% | ADD +27.1% |
| 8 | Mawer Investment Management Ltd. | 1,245,467 | $156.0M | 0.4% | — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 558,066 | $69.9M | 0.2% | NEW |
| 10 | DODGE & COX | 17,324 | $2.2M | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 23,456,714 | — | $2.9B | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 558,066 | — | $69.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 30,100 | 0 | -100.0% | $0.00 | 2025-Q4 |
| NORGES BANK | EXIT | 22,249,689 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 22,249,689 | — | $3.0B | 2025-Q2 |
| FMR LLC | ADD | 10,675,331 | 13,564,085 | +27.1% | $1.8B | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 5,002,100 | 2,872,100 | -42.6% | $381.0M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 305,352 | 27,387 | -91.0% | $3.6M | 2025-Q1 |
| NORGES BANK | EXIT | 20,983,649 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 3,238,453 | 5,002,100 | +54.5% | $565.8M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 12,609,477 | — | $1.4B | 2024-Q3 |
24 unique insiders with 8 transactions. Net insider value: $642.5K ($1.1M bought, $485.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | I | 5,314 | $94.41 | $501.7K |
| Apr 27, 2026 | STARKS DANIEL J | Director | BUY | 10,000 | $92.65 | $926.5K |
| Apr 24, 2026 | Ahuja Nita | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | Babineaux-Fontenot Claire | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | Blount Sally E. | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | Gonzalez Patricia Paola | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | Kumbier Michelle | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | McDew Darren W | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | McKinstry Nancy | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | McKinstry Nancy | Director | A | 2,305 | $0.00 | $0.00 |
| Apr 24, 2026 | Roman Michael F | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | O'Grady Michael | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | O'Grady Michael | Director | A | 5,929 | $0.00 | $0.00 |
| Apr 24, 2026 | STARKS DANIEL J | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | STARKS DANIEL J | Director | A | 7,105 | $0.00 | $0.00 |
| Apr 24, 2026 | Stratton John G | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 24, 2026 | Conroy Kevin T | Director | A | 2,286 | $0.00 | $0.00 |
| Apr 23, 2026 | Boudreau Philip P | EVP AND CFO | I | 8,909 | $92.04 | $820.0K |
| Apr 23, 2026 | Boudreau Philip P | EVP AND CFO | BUY | 2,200 | $91.50 | $201.3K |
| Mar 31, 2026 | Roman Michael F | Director | A | 367 | $102.67 | $37.7K |
| Mar 31, 2026 | Ahuja Nita | Director | A | 102 | $102.67 | $10.5K |
| Mar 31, 2026 | Alpern Robert J | Director | A | 76 | $102.67 | $7.8K |
| Mar 31, 2026 | Stratton John G | Director | A | 382 | $102.67 | $39.2K |
| Mar 31, 2026 | Gonzalez Patricia Paola | Director | A | 321 | $102.67 | $33.0K |
| Mar 23, 2026 | ORVILLE JACOB A | Senior Vice President | A | 13,255 | $0.00 | $0.00 |
| Mar 2, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | SELL | 585 | $115.58 | $67.6K |
| Mar 2, 2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | SELL | 613 | $115.58 | $70.9K |
| Mar 2, 2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | SELL | 263 | $115.58 | $30.4K |
| Mar 2, 2026 | Shroff Eric | Senior Vice President | SELL | 709 | $115.58 | $81.9K |
| Mar 2, 2026 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | SELL | 885 | $115.58 | $102.3K |
| Mar 2, 2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | SELL | 1,144 | $115.58 | $132.2K |
| Feb 27, 2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | F | 4,040 | $116.26 | $469.7K |
| Feb 27, 2026 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | F | 4,997 | $116.26 | $581.0K |
| Feb 27, 2026 | Boudreau Philip P | EVP AND CFO | F | 7,441 | $116.26 | $865.1K |
| Feb 27, 2026 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | F | 8,577 | $116.26 | $997.2K |
| Feb 27, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | F | 1,142 | $116.26 | $132.8K |
| Feb 27, 2026 | Ford Robert B | CHAIRMAN AND CEO | F | 30,308 | $116.26 | $3.5M |
| Feb 27, 2026 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | F | 6,615 | $116.26 | $769.1K |
| Feb 27, 2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | F | 1,421 | $116.26 | $165.2K |
| Feb 27, 2026 | Shroff Eric | Senior Vice President | F | 1,384 | $116.26 | $160.9K |
| Feb 27, 2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | F | 4,630 | $116.26 | $538.3K |
| Feb 24, 2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | A | 61,964 | $0.00 | $0.00 |
| Feb 24, 2026 | Shroff Eric | Senior Vice President | A | 44,821 | $0.00 | $0.00 |
| Feb 24, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | A | 5,373 | $0.00 | $0.00 |
| Feb 24, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | A | 22,151 | $0.00 | $0.00 |
| Feb 24, 2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | A | 15,418 | $0.00 | $0.00 |
| Feb 24, 2026 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | A | 21,644 | $0.00 | $0.00 |
| Feb 24, 2026 | Ford Robert B | CHAIRMAN AND CEO | A | 83,464 | $0.00 | $0.00 |
| Feb 24, 2026 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | A | 18,502 | $0.00 | $0.00 |
| Feb 24, 2026 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | A | 76,273 | $0.00 | $0.00 |
11 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 7 neutral. Avg impact: 3.8/10.
BULLISH
ANALYST-UPGRADE
4/10
5 firms acted on ABT: Freedom Broker, Benchmark, Jefferies, Oppenheimer, Piper Sandler
May 31, 2026
MIXED
ANALYST-UPGRADE
4/10
Freedom Broker upgrades ABT to Buy — PT $120 (+32% upside) on cluster action
May 1, 2026
NEUTRAL
COURT-RULING
1/10
The Ninth Circuit affirmed the district court's dismissal of a pro se plaintiff's employment claims
May 28, 2026
NEUTRAL
CLUSTER
2/10
Insider cluster at Abbott Laboratories shows two open-market purchases totaling $1.13M by the CFO an
Apr 28, 2026
NEUTRAL
8-K
2/10
Abbott Laboratories filed an 8-K reporting the adoption of amended and restated bylaws effective Apr
Apr 27, 2026
NEUTRAL
8-K
4/10
Abbott Laboratories has preliminarily agreed to settle a shareholder derivative lawsuit related to i
Apr 17, 2026
BEARISH
8-K
8/10
Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase,
Apr 16, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable. Two court rulings against
Mar 30, 2026
BULLISH
8-K
8/10
Abbott Laboratories completed the acquisition of Exact Sciences for $105.00 per share in cash, estab
Mar 23, 2026
NEUTRAL
DEFA14A
3/10
This DEFA14A filing is a definitive additional proxy soliciting material from Abbott Laboratories (A
Mar 13, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Abbott Laboratories over the past week includes open-market sal
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (71% buy). Based on 34 analysts: 10 strong buy, 14 buy, 10 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$117.29 mean target
+28.5% upside
Strong Buy (1.67)
$92.00 Low
$135.00 High
| Metric | Value |
|---|---|
| Current Price | $91.25 |
| Target Low | $92.00 |
| Target Mean | $117.29 |
| Target Median | $115.00 |
| Target High | $135.00 |
| # Analysts | 24 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.28 | $1.26 | $1.29 | 1.3% | -0.1% | 0↑ 2↓ | $12.5B | 12.5% | 22 |
| Next Q 2026-09-30 |
$1.42 | $1.40 | $1.45 | 9.2% | -0.0% | 1↑ 1↓ | $13.1B | 15.6% | 22 |
| Current FY 2026-12-31 |
$5.48 | $5.40 | $5.71 | 6.5% | -0.0% | 1↑ 2↓ | $50.3B | 13.5% | 24 |
| Next FY 2027-12-31 |
$6.06 | $5.95 | $6.20 | 10.6% | -0.0% | 0↑ 2↓ | $54.8B | 9.0% | 24 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.276 | |
| 7d ago | $1.277 | -0.001 |
| 30d ago | $1.277 | -0.001 |
| 60d ago | $1.348 | -0.072 |
| 90d ago | $1.385 | -0.109 |
13 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | Benchmark | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 9, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 31, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | Freedom Broker | UPGRADE | Hold | Buy |
| Jan 23, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 23, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Jan 5, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 14 | 10 | 0 | 0 | 71% | |
| May 1, 2026 | 10 | 15 | 10 | 0 | 0 | 71% | |
| Apr 1, 2026 | 10 | 16 | 9 | 0 | 0 | 74% | |
| Mar 1, 2026 | 10 | 15 | 10 | 0 | 0 | 71% | |
| Feb 1, 2026 | 10 | 15 | 10 | 0 | 0 | 71% | |
| Jan 1, 2026 | 10 | 14 | 11 | 0 | 0 | 69% | |
| Dec 1, 2025 | 10 | 14 | 11 | 0 | 0 | 69% | |
| Nov 1, 2025 | 10 | 14 | 12 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
6 members of Congress traded this stock: 3 buys, 4 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | Josh Gottheimer | D | HOUSE | SELL | $1,001 - $15,000 | Abbott Laboratories | Jun 4, 2026 (9d) |
| Mar 24, 2026 | Laura Friedman | D | HOUSE | EXCHANGE | $1,001 - $15,000 | Abbott Laboratories | Apr 20, 2026 (28d) |
| Mar 19, 2026 | Rich McCormick | R | HOUSE | BUY | $1,001 - $15,000 | Abbott Laboratories | Apr 8, 2026 (21d) |
| Mar 4, 2026 | Michael McCaul | R | HOUSE | SELL | $1,001 - $15,000 | Abbott Laboratories | Apr 10, 2026 (38d) |
| Feb 27, 2026 | Michael McCaul | R | HOUSE | SELL | $15,001 - $50,000 | Abbott Laboratories | Mar 12, 2026 (14d) |
| Feb 10, 2026 | Gilbert Cisneros | D | HOUSE | SELL | $1,001 - $15,000 | Abbott Laboratories | Mar 10, 2026 (29d) |
| Feb 5, 2026 | Michael McCaul | R | HOUSE | BUY | $15,001 - $50,000 | Abbott Laboratories | Mar 12, 2026 (36d) |
| Jan 29, 2026 | Thomas Kean Jr | R | HOUSE | BUY | $1,001 - $15,000 | Abbott Laboratories | Feb 20, 2026 (23d) |
71°
Bullish
Bearish
Neutral
Bullish
10 mentions
6 bullish
0 bearish
10 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Rotation into consumer staples/defensives - best plays?
▲ 1
💬 0
⚡ 0.5
ABOTT(ABT) opinions
▲ 1
💬 0
⚡ 0.5
Let’s talk about Abbot Labs (ABT)
▲ 1
💬 0
⚡ 0.5
Abbott: A Hidden Gem
▲ 1
💬 0
⚡ 0.5
$ABT is about to pop off tomorrow
▲ 1
💬 1
⚡ 0.5
Jul 15, 2026
earnings_calendar
ABT Q2 2026 Earnings Before Market Open — 2026-07-15
EPS est: $1.39 | Rev est: $12.1B
Jun 8, 2026
Enforcement
United States v. James Abbott
Court ruling from Court of Appeals for the D.C. Circuit. Docket: 25-5352
Jun 8, 2026
Enforcement
State v. Abbott
Court ruling from Ohio Court of Appeals. Docket: CA2024-12-084
May 28, 2026
Enforcement
Arakji v. Abbott Laboratories, Inc.
Court ruling from Court of Appeals for the Ninth Circuit. Docket: 24-7785
May 18, 2026
dark_pool
Dark Pool: ABT — 12.1M shares, 180,148 trades
Week starting 2026-05-18. Total ATS volume: 12,123,584 shares across 180,148 trades.
May 14, 2026
Clinical Trial
Quick Epidural Top-up With Alkalinized Lidocaine for Emergent Caesarean Delivery
Phase Phase 3 — COMPLETED
May 11, 2026
dark_pool
Dark Pool: ABT — 16.6M shares, 203,766 trades
Week starting 2026-05-11. Total ATS volume: 16,639,220 shares across 203,766 trades.
May 4, 2026
dark_pool
Dark Pool: ABT — 14.5M shares, 175,482 trades
Week starting 2026-05-04. Total ATS volume: 14,527,430 shares across 175,482 trades.
May 4, 2026
Enforcement
MacTruong v. Abbott
Court ruling from Court of Appeals for the Fifth Circuit. Docket: 25-50364
Apr 27, 2026
dark_pool
Dark Pool: ABT — 15.8M shares, 181,628 trades
Week starting 2026-04-27. Total ATS volume: 15,800,587 shares across 181,628 trades.
Apr 21, 2026
short_interest
FTD: ABT — 6,240 shares ($0.6M) failed to deliver
Settlement: 20260421, Price: $96.00, FTD Value: $599,040, ABBOTT LABS;COM NPV
Apr 20, 2026
Clinical Trial
Use of Preoperative Sodium Bicarbonate Among Women With Obstructed Labor
Phase Phase 3 — COMPLETED
Apr 20, 2026
dark_pool
Dark Pool: ABT — 13.4M shares, 169,760 trades
Week starting 2026-04-20. Total ATS volume: 13,370,067 shares across 169,760 trades.
Apr 16, 2026
earnings_calendar
ABT Q1 2026 Earnings Before Market Open — 2026-04-16
Apr 14, 2026
earnings_calendar
ABT Q1 2026 Earnings Before Market Open — 2026-04-14
EPS est: $1.16 | Rev est: $11.1B
Apr 14, 2026
earnings_calendar
ABT Q1 2026 Earnings Before Market Open — 2026-04-14
Apr 13, 2026
dark_pool
Dark Pool: ABT — 20.1M shares, 226,930 trades
Week starting 2026-04-13. Total ATS volume: 20,111,741 shares across 226,930 trades.
Apr 13, 2026
short_interest
FTD: ABT — 68,600 shares ($6.9M) failed to deliver
Settlement: 20260413, Price: $100.30, FTD Value: $6,880,580, ABBOTT LABS;COM NPV
Apr 7, 2026
Clinical Trial
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva
Phase Phase 3 — COMPLETED
Apr 6, 2026
dark_pool
Dark Pool: ABT — 10.4M shares, 131,756 trades
Week starting 2026-04-06. Total ATS volume: 10,434,791 shares across 131,756 trades.
Apr 3, 2026
Clinical Trial
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
Phase Phase 3 — COMPLETED
Mar 30, 2026
dark_pool
Dark Pool: ABT — 8.4M shares, 109,666 trades
Week starting 2026-03-30. Total ATS volume: 8,374,600 shares across 109,666 trades.
Mar 30, 2026
Enforcement
1:25-cv-08650 Doe [#151] v. Abbott Laboratories
Court ruling from United States District Court for the Northern District of Illinois. Docket: N/A
Mar 27, 2026
short_volume
Short Volume: ABT — 55.0% short (3.1M / 5.6M)
Short: 3,074,730 | Exempt: 20,296 | TRF Vol: 5,589,893 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Feb 24, 2026
Clinical Trial
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
Phase Phase 2 — COMPLETED